Cogent Biosciences, Inc. (COGT) Balance Sheet
As of 2026-06-30 (10-Q), Cogent Biosciences, Inc. (COGT) reported total assets of $834.5M, total liabilities of $302.2M and shareholders' equity of $532.4M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $181.2M. Long-term debt: $223.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
COGTCogent Biosciences, Inc.Follow COGT — free
—
Price chart with a free account
- Market cap
- 5.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 55.7 | 37.4 | 242.2 | 219.7 | 139.9 | 53.2 | 98.2 | 312.0 | 181.2 | |
| Short-term investments | 22.9 | — | — | 0.0 | 119.4 | 212.5 | 188.9 | 588.8 | 611.1 | |
| Receivables | 1.7 | 2.0 | — | — | — | — | — | — | — | |
| Current assets | 81.0 | 40.6 | 244.9 | 222.6 | 265.0 | 270.8 | 296.5 | 910.4 | 804.8 | |
| Total assets | 85.9 | 49.4 | 250.9 | 232.1 | 300.8 | 313.4 | 327.9 | 937.6 | 834.5 | |
| Current liabilities | 24.9 | 13.2 | 13.1 | 17.1 | 26.8 | 38.2 | 55.7 | 64.0 | 59.3 | |
| Long-term debt | — | — | — | — | — | — | 0.0 | 222.9 | 223.5 | |
| Total liabilities | 25.7 | 17.7 | 16.2 | 17.9 | 45.1 | 55.6 | 71.6 | 301.2 | 302.2 | |
| Shareholders' equity | 60.2 | 31.8 | 234.7 | 214.2 | 255.7 | 257.8 | 256.3 | 636.4 | 532.4 |
USD millions · SEC XBRL
Cogent Biosciences, Inc. — questions
- How much cash does Cogent Biosciences, Inc. have?
- $181.2M in cash and cash equivalents as of 2026-06-30.
- How much debt does Cogent Biosciences, Inc. have?
- $223.5M of long-term debt as of 2026-06-30.
- What are Cogent Biosciences, Inc.'s total assets?
- $834.5M as of 2026-06-30.
- What is Cogent Biosciences, Inc.'s shareholders' equity?
- $532.4M as of 2026-06-30.
Every figure on this page comes from Cogent Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.